Related Experiment Video
Updated: Aug 17, 2026
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
Multigene targeting with antisense oligodeoxynucleotides: an exploratory study using primary human leukemia cells
Joanna B Opalinska1, Boguslaw Machalinski, Janina Ratajczak
1Authors' Affiliations: Hematology and Pathology, Pommeranian Medical University, Szczecin, Poland.
Purpose:
We previously reported that the c-myb and Vav proto-oncogenes are amenable to silencing with antisense oligodeoxynucleotides and that inhibition of either impairs leukemic cell growth. Because the expression of these genes is not known to be linked, we sought to determine the therapeutic value of silencing both genes simultaneously in K562 and primary patient (n = 9) chronic myelogenous leukemia cells.
Experimental Design:
K562 and primary chronic myelogenous leukemia cells were exposed to antisense oligodeoxynucleotides (alone or in combination) for 24 or 72 hours and then cloned in methylcellulose cultures. Effects on K562 cluster, and blast-forming unit-erythroid colonies and granulocyte-macrophage colony-forming units were determined and correlated with the ability to down-regulate the targeted mRNA.
Results:
After 24-hour exposure, K562 cell growth was inhibited in a sequence specific, dose-responsive manner with either c-myb or Vav antisense oligodeoxynucleotides. Exposure to both oligodeoxynucleotides simultaneously considerably enhanced growth inhibition and accelerated apoptosis. Primary cell results were more complex. After 24- and 72-hour exposures to either anti-vav or anti-myb antisense oligodeoxynucleotides, equivalent colony-forming unit inhibition was observed. Exposing cells to both antisense oligodeoxynucleotides simultaneously for 24 hours did not result in additional inhibition of colony formation. However, after 72-hour incubation with both oligodeoxynucleotides, colony formation was diminished significantly when compared with either oligodeoxynucleotides alone (from approximately 30% to approximately 78% for granulocyte-macrophage colony-forming unit; approximately 50% to approximately 80% for blast-forming unit-erythroid).
Conclusions:
We hypothesize that exposing primary leukemic cells to antisense oligodeoxynucleotides targeted to two, or possibly more, genes might significantly augment the therapeutic utility of these molecules.
Insights
Simultaneously silencing c-myb and Vav proto-oncogenes with antisense oligodeoxynucleotides significantly enhanced leukemia cell growth inhibition and apoptosis. This dual-targeting approach shows promise for augmenting therapeutic utility in chronic myelogenous leukemia treatment.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- Antisense oligodeoxynucleotides targeting c-myb and Vav proto-oncogenes inhibit leukemic cell growth individually.
- The potential therapeutic benefit of simultaneously silencing both genes in chronic myelogenous leukemia (CML) is unexplored.
Purpose of the Study:
- To investigate the therapeutic value of concurrently silencing c-myb and Vav proto-oncogenes in K562 and primary CML cells.
- To determine if combined antisense oligodeoxynucleotide therapy enhances leukemic cell growth inhibition and apoptosis.
Main Methods:
- K562 and primary CML cells were treated with antisense oligodeoxynucleotides targeting c-myb and/or Vav.
- Cells were incubated for 24 or 72 hours, followed by methylcellulose cloning assays.
- Effects on colony formation were correlated with mRNA downregulation.
Main Results:
- Simultaneous silencing of c-myb and Vav in K562 cells significantly enhanced growth inhibition and accelerated apoptosis compared to single-gene silencing.
- In primary CML cells, combined 72-hour treatment with both antisense oligodeoxynucleotides significantly reduced colony formation (up to 78% for granulocyte-macrophage and 80% for blast-forming unit-erythroid colonies).
- A 24-hour combined treatment did not yield additional inhibition in primary cells, suggesting a time-dependent effect.
Conclusions:
- Simultaneous silencing of multiple proto-oncogenes using antisense oligodeoxynucleotides may significantly enhance therapeutic efficacy in leukemia.
- This combinatorial approach holds potential for augmenting the clinical utility of antisense technology in cancer treatment.
